Alliances
Pharming paid Novartis an upfront fee of $20 million for the asset, a small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA PI3K with immune-modulating and potentially anti-neoplastic activities.
Under the terms of the deal with Yale University, Yale researchers led by Geoff Chupp will conduct discovery research on targets associated with pulmonary diseases, then turn over the candidates to CureVac for preclinical and clinical development.
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, announced a research partnership with leading scientists in the Perelman School of Medicine at the University of Pennsylvania focused on studying the pathological mechanisms of TDP-43 misfolding and aggregation.
Quanta Dialysis Technologies Ltd, a pioneering British medical technology company developing a personal haemodialysis system for patient use at home and in the clinic, announces that it has selected Benchmark Electronics Inc., a global provider of manufacturing, engineering and design services, as its production partner for the SC+ haemodialysis machine.
More than three million citizens across the Leeds City Region are set to benefit as senior leaders from the healthtech industry, the regional enterprise partnership, the NHS, local authorities, and five universities announced a dynamic, new partnership to accelerate health technology innovation.
Privately-held Oncologie will conduct a Phase II study of the combination study for patients who have failed at least one line of treatment for gastric or gastroesophageal cancer.
The deal has a flexible framework, which will allow for a variety of projects at different stages of development over several years.
There are numerous ongoing projects between healthcare institutions and biopharmaceutical companies that are focusing on deep dives into patients’ genes, hoping to provide insights that can lead to newer, better drugs developed faster. But they’re not without their controversies.
Cytovation AS and Specialized Medical Services-oncology BV announce that SMS-oncology has been selected as the CRO to conduct the phase I/II clinical trial with CyPep-1 in patients with advanced solid cancers.
CINCINNATI, August 7, 2019 - Blue Water Vaccines, a Cincinnati-based biotechnology startup, has signed an agreement with Ology Bioservices, Inc.
PRESS RELEASES